Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simon, G. R.
Right arrow Articles by Wagner, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simon, G. R.
Right arrow Articles by Wagner, H.
(Chest. 2003;123:259S-271S.)
© 2003 American College of Chest Physicians

Small Cell Lung Cancer*

George R. Simon, MD, FCCP and Henry Wagner, MD

* From the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Correspondence to: George R. Simon, MD, FCCP, 12902 Magnolia Dr, Suite 3170, Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612; e-mail: Simongr{at}moffitt.usf.edu

Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.

Key Words: carboplatin • chemotherapy • cisplatin • etoposide • irinotecan • paclitaxel • prophylactic cranial irradiation • radiation therapy • small cell lung cancer




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Granetzny, A. Boseila, W. Wagner, G. Krukemeyer, U. Vogt, E. Hecker, O. M. Koch, and F. Klinke
Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival.
Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 212 - 216.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.